Center-Authored Papers

Filters: Author is Price, Douglas K  [Clear All Filters]
Journal Article
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW et al..  2010.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.. The Journal of urology. 184(6):2297-302. Abstract
Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JKV, Tangen CM, Leach RJ et al..  2014.  Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial.. Urology. Abstract
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.  2010.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 70(6):584-90. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM et al..  2016.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.. Cancer. 122(15):2332-2340. Abstract
Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JKV et al..  2015.  Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.. Urology. 85(3):616-20. Abstract
Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM et al..  2015.  Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial.. PloS one. 10(5):e0126672. Abstract
Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JKV, Tang L et al..  2011.  Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.. Cancer causes & control : CCC. 22(8):1121-31. Abstract